EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	95.85M
Revenue (ttm)	50.19M
Net Income (ttm)	6.24M
Shares Out	452.11M
EPS (ttm)	0.01
PE Ratio	15.41
Forward PE	14.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,015
Average Volume	903,844
Open	21.30
Previous Close	21.20
Day's Range	21.30 - 21.97
52-Week Range	18.40 - 33.80
Beta	0.47
RSI	49.92
Earnings Date	Mar 21, 2025

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucos...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 317
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.